TrialThe oncologist2013

An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

Francisco J Esteva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.